These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 30054148)

  • 1. Strategies to increase cardioprotection through cardioprotective chemokines in chemotherapy-induced cardiotoxicity.
    Haybar H; Shahrabi S; Deris Zayeri Z; Pezeshki S
    Int J Cardiol; 2018 Oct; 269():276-282. PubMed ID: 30054148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving the preclinical models for the study of chemotherapy-induced cardiotoxicity: a Position Paper of the Italian Working Group on Drug Cardiotoxicity and Cardioprotection.
    Madonna R; Cadeddu C; Deidda M; Mele D; Monte I; Novo G; Pagliaro P; Pepe A; Spallarossa P; Tocchetti CG; Zito C; Mercuro G
    Heart Fail Rev; 2015 Sep; 20(5):621-31. PubMed ID: 26168714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Routine Prophylactic Cardioprotective Therapy Should Not Be Given to All Recipients of Potentially Cardiotoxic Cancer Chemotherapy.
    Davis MK; Virani SA
    Can J Cardiol; 2016 Jul; 32(7):926-30. PubMed ID: 27245087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of strain-targeted cardioprotection for prevention of chemotherapy-induced cardiotoxicity.
    Nolan MT; Plana JC; Thavendiranathan P; Shaw L; Si L; Marwick TH
    Int J Cardiol; 2016 Jun; 212():336-45. PubMed ID: 27060722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of anthracycline-mediated cardiotoxicity and preventative strategies in women with breast cancer.
    Varghese SS; Eekhoudt CR; Jassal DS
    Mol Cell Biochem; 2021 Aug; 476(8):3099-3109. PubMed ID: 33835331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Routine Prophylactic Cardioprotective Therapy Should Be Given to All Recipients at Risk of Cardiotoxicity From Cancer Chemotherapy.
    Abdel-Qadir H; Nolan MT; Thavendiranathan P
    Can J Cardiol; 2016 Jul; 32(7):921-5. PubMed ID: 27343746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Guarding the heart: How SGLT-2 inhibitors protect against chemotherapy-induced cardiotoxicity: SGLT-2 inhibitors and chemotherapy-induced cardiotoxicity.
    Vafa RG; Sabahizadeh A; Mofarrah R
    Curr Probl Cardiol; 2024 Mar; 49(3):102350. PubMed ID: 38128634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are cardioprotective effects of NO-releasing drug molsidomine translatable to chronic anthracycline cardiotoxicity settings?
    Lenčová-Popelová O; Jansová H; Jirkovský E; Bureš J; Jirkovská-Vávrová A; Mazurová Y; Reimerová P; Vostatková L; Adamcová M; Hroch M; Pokorná Z; Kovaříková P; Šimůnek T; Štěrba M
    Toxicology; 2016 Nov; 372():52-63. PubMed ID: 27816693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardioprotective effects of inorganic nitrate/nitrite in chronic anthracycline cardiotoxicity: Comparison with dexrazoxane.
    Lenčová-Popelová O; Jirkovský E; Jansová H; Jirkovská-Vávrová A; Vostatková-Tichotová L; Mazurová Y; Adamcová M; Chládek J; Hroch M; Pokorná Z; Geršl V; Šimůnek T; Štěrba M
    J Mol Cell Cardiol; 2016 Feb; 91():92-103. PubMed ID: 26724189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiotoxicity in anthracycline therapy: Prevention strategies.
    Cruz M; Duarte-Rodrigues J; Campelo M
    Rev Port Cardiol; 2016 Jun; 35(6):359-71. PubMed ID: 27255173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antioxidant Approach as a Cardioprotective Strategy in Chemotherapy-Induced Cardiotoxicity.
    Cadeddu Dessalvi C; Deidda M; Noto A; Madeddu C; Cugusi L; Santoro C; López-Fernández T; Galderisi M; Mercuro G
    Antioxid Redox Signal; 2021 Mar; 34(7):572-588. PubMed ID: 32151144
    [No Abstract]   [Full Text] [Related]  

  • 12. Anthracycline-associated cardiotoxicity in adults: systematic review on the cardioprotective role of beta-blockers.
    Barbosa RR; Bourguignon TB; Torres LD; Arruda LS; Jacques TM; Serpa RG; Calil OA; Barbosa LFM
    Rev Assoc Med Bras (1992); 2018 Aug; 64(8):745-754. PubMed ID: 30673046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiotoxicity linked to anticancer agents and cardioprotective strategy.
    Khairnar SI; Kulkarni YA; Singh K
    Arch Pharm Res; 2022 Oct; 45(10):704-730. PubMed ID: 36306018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gp130-mediated STAT3 activation by S-propargyl-cysteine, an endogenous hydrogen sulfide initiator, prevents doxorubicin-induced cardiotoxicity.
    Wu J; Guo W; Lin SZ; Wang ZJ; Kan JT; Chen SY; Zhu YZ
    Cell Death Dis; 2016 Aug; 7(8):e2339. PubMed ID: 27537522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiblastic drug-induced cardiotoxicity and cardioprotection: a compendium.
    Mercuro G
    J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e1-e2. PubMed ID: 27755236
    [No Abstract]   [Full Text] [Related]  

  • 16. Cardioprotective role of β-blockers and angiotensin antagonists in early-onset anthracyclines-induced cardiotoxicity in adult patients: a systematic review and meta-analysis.
    Yun S; Vincelette ND; Abraham I
    Postgrad Med J; 2015 Nov; 91(1081):627-33. PubMed ID: 26399268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy-induced cardiotoxicity in children.
    Bansal N; Amdani S; Lipshultz ER; Lipshultz SE
    Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):817-832. PubMed ID: 28679288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy cardiotoxicity: cardioprotective drugs and early identification of cardiac dysfunction.
    Di Lisi D; Leggio G; Vitale G; Arrotti S; Iacona R; Inciardi RM; Nobile D; Bonura F; Novo G; Russo A; Novo S
    J Cardiovasc Med (Hagerstown); 2016 Apr; 17(4):270-5. PubMed ID: 25501904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis.
    Kalam K; Marwick TH
    Eur J Cancer; 2013 Sep; 49(13):2900-9. PubMed ID: 23706982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary Cardioprotection Reduces Mortality in Lymphoma Patients with Increased Risk of Anthracycline Cardiotoxicity, Treated by R-CHOP Regimen.
    Długosz-Danecka M; Gruszka AM; Szmit S; Olszanecka A; Ogórka T; Sobociński M; Jaroszyński A; Krawczyk K; Skotnicki AB; Jurczak W
    Chemotherapy; 2018; 63(4):238-245. PubMed ID: 30372698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.